In a subsequent study, the aforementioned immunoliposome platform was used to encapsulate carvedilol, intended to block neoangiogenesis within the tumor (69), and to conjugate CD47 and PD-L1 blocking antibodies via reactive oxygen species (ROS)-sensitive thioketal linkers (70). The gene discussed is CD47; the disease is neoplasm.